Education & Training
- Gynecologic Oncology Fellowship Program
- Pediatric Hematology/Oncology Fellowship Program
- Therapeutic Radiology Residency Training Program
- Yale Medical Oncology-Hematology Program
Targeting a Deadly Type of Uterine Cancer -
Endometrial cancer often has a good prognosis. Patients with the more frequently diagnosed type I are often cured. Type II, however, is responsible for most of the recurrences and deaths that occur in endometrial cancer. Uterine Serous Carcinoma (USC), the most aggressive kind of type II endometrial cancer, accounts for just 10 percent of endometrial tumors and is particularly deadly.